Devyser Diagnostics AB (DVYSR) AI Stock Analysis

Top Page

Devyser Diagnostics AB

(Nasdaq OMX AB:DVYSR)

Select Model

Rating:57Neutral

Price Target:SEK 57.00▲(3.64% Upside)

Action:reiterated

Date:10/28/26

The score is primarily supported by improving financial performance (return to profitability, strong margins, and low leverage). It is held back by mixed technicals (negative MACD and below longer-term moving averages) and a high P/E valuation with no dividend yield data to offset the premium.

Positive Factors

Profitability inflectionThe return to positive earnings alongside strong gross and operating margins indicates a meaningful improvement in the economics of the business. If maintained, this profitability provides greater capacity to fund product development, commercial expansion, and operations without relying as heavily on external capital.

Negative Factors

Revenue contractionA declining revenue base limits the durability of the current earnings improvement because margin gains cannot compound indefinitely without renewed demand. Continued contraction could weaken scale benefits, constrain commercial investment, and make future growth more dependent on further efficiency gains.

Devyser Diagnostics AB (DVYSR) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 928.94M
Dividend Yield: ―
Average Volume (3M): 16.71K
Price to Earnings (P/E): 59.8
Beta (1Y): 0.55
Revenue Growth: 6.51%
EPS Growth: ―
Country: Sweden
Employees: 110
Sector: General
Sector Strength: 55
Industry: Medical - Devices

Devyser Diagnostics AB Business Overview & Revenue Model

Company Description

Headquartered in Hägersten, Sweden, and established in 2004, Devyser Diagnostics AB (publ) specializes in the development, manufacturing, and global sale of advanced diagnostic kits and solutions for DNA testing. The company's innovative products are...

How the Company Makes Money

Devyser Diagnostics makes money primarily by selling molecular diagnostic products to clinical laboratories and other healthcare testing providers. Key revenue streams include: (1) sales of diagnostic assay kits (reagents/consumables) used to run spe...

Devyser Diagnostics AB Financial Statement Overview

Summary

Fundamentals are improving with a clear profitability inflection in TTM (positive net income, ~80% gross margin, and improved EBIT/EBITDA margins) and a conservatively levered balance sheet (low debt-to-equity ~0.14). Offsets include slightly negative TTM revenue growth (about -2.8%) and uneven cash conversion (FCF positive but meaningfully below net income), keeping the score in the mid-range.

Income Statement

62Positive

Balance Sheet

74Positive

Cash Flow

55Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	250.40M	250.50M	216.90M	169.30M	126.61M	93.48M
Gross Profit	195.80M	201.90M	172.70M	148.10M	105.77M	74.66M
EBITDA	53.50M	37.70M	-26.40M	-43.80M	-46.02M	-18.05M
Net Income	15.30M	-8.40M	-61.50M	-53.60M	-45.95M	-20.73M
Balance Sheet
Total Assets	493.10M	469.70M	473.80M	510.10M	500.63M	456.87M
Cash, Cash Equivalents and Short-Term Investments	81.00M	77.50M	144.50M	262.90M	363.60M	377.64M
Total Debt	45.80M	51.90M	59.10M	74.80M	21.20M	12.96M
Total Liabilities	112.10M	115.40M	124.80M	125.00M	69.19M	40.18M
Stockholders Equity	381.00M	354.30M	349.10M	385.10M	431.44M	416.68M
Cash Flow
Free Cash Flow	20.50M	6.70M	-123.70M	-101.70M	-66.30M	-25.28M
Operating Cash Flow	36.00M	8.20M	-46.80M	-69.70M	-40.50M	-16.48M
Investing Cash Flow	-58.50M	-70.70M	-76.90M	-32.00M	-23.86M	-10.32M
Financing Cash Flow	3.10M	-2.80M	7.80M	-200.00K	48.94M	395.93M

Devyser Diagnostics AB Technical Analysis

Technical Analysis SentimentNeutral

Last Price55.00

Price Trends

50DMA54.45Positive

100DMA61.99Negative

200DMA76.70Negative

Market Momentum

MACD0.40Negative

RSI54.54Neutral

STOCH77.52Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:DVYSR, the sentiment is Neutral. The current price of 55.00 is above the 20-day moving average (MA) of 52.22, above the 50-day MA of 54.45, and below the 200-day MA of 76.70, indicating a neutral trend. The MACD of 0.40 indicates Negative momentum. The RSI at 54.54 is Neutral, neither overbought nor oversold. The STOCH value of 77.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:DVYSR.

Devyser Diagnostics AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

SE:DVYSR against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:DVYSR	57Neutral	SEK 928.94M	59.78	―	―	6.51%	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
SE:IMMNOV	43Neutral	SEK 33.70M	-0.30	-279.07%	―	31.66%	79.68%
SE:PROGEN	41Neutral	SEK 74.32M	-0.20	-229.18%	―	143.94%	70.95%
SE:CLBIO	39Underperform	SEK 371.09M	-28.83	―	―	54.37%	52.22%
SE:BOUL	38Underperform	SEK 40.19M	-2.31	-58.52%	―	-16.09%	78.68%
SE:SCIB	30Underperform	SEK 174.38M	-0.78	-303.61%	―	51.21%	42.24%

* General Sector Average

Performance Comparison

SE:DVYSR and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:DVYSR	Devyser Diagnostics AB	55.00	-68.00	-55.28%
SE:BOUL	Boule Diagnostics AB	1.03	-5.45	-84.03%
SE:IMMNOV	Immunovia AB	0.05	-0.27	-84.28%
SE:SCIB	SciBase Holding AB	12.35	-13.24	-51.74%
SE:PROGEN	Prostatype Genomics AB	0.11	-0.12	-52.86%
SE:CLBIO	Corline Biomedical AB	14.20	-5.75	-28.82%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026

Devyser Diagnostics AB AI Stock Analysis

Top Page